'Incredibly Exciting': Anne L. Peters, MD, What are You so Exciting For?

There is interesting news, medicine for glucose lowering was studied how it is effective for the diabetics type 2 with cardiovascular problems. What studies found is that Empagliflozin, the same family medicine as Invokana, reduce risk of heart attacks.
 It is old time well known that one who pay order the music to play. So, who paid for the studies?

"All the authors were involved in the study design and had access to the data, which were analyzed by one of the study sponsors, Boehringer Ingelheim". 

 Empagliflozin (trade name Jardiance) is a medicine  was developed by Boehringer Ingelheim and Eli Lilly and Company.
WOW! No Comments!
So, now I can take a look what studies found, and figure out, do I need to trust in studies, and do I am,  diabetic type 2, safe to take the medicine they present it is good to control blood sugar and will reduce risk of heart attack or MI for me?  I do I need to trust in Anne Peters and crown her?

Hello. I'm Dr Anne Peters. Approximately 1 year ago I brought you news of the EMPA-REG trial. I was quite excited about the value of empagliflozin for reducing cardiovascular risk in patients with type 2 diabetes. Now, the US Food and Drug Administration finally agrees and has added a new indication for empagliflozin—to reduce cardiovascular death in patients with type 2 diabetes and known cardiovascular disease. http://ift.tt/2hvfg9R

So, what Anne Peters is so Exciting? Is this really true that  empagliflozin for reducing cardiovascular risk in patients with type 2 diabetes? Well, let us take a look at the trial, which according to Anne Peters and US FDA confirmed that this type of medicine really do great job.

FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. 09.10. 2015
The FDA warned about potentially fatal side effects of Invokana and other SGLT2 inhibitor drugs. Invokana lawyers filed lawsuits on behalf of people who say they these drugs injured them. SGLT2 inhibitors treat Type 2 diabetes but may trigger dangerous levels of blood acids and increase the risk of urinary tract infections. Studies also show they may increase the risk of stroke, heart attack and kidney problems that may require hospitalization. http://ift.tt/2hMmK4b

 WOW! No, I will wait a little bit longer to see, when finally this medicine would be out of market. Actos is already recalled. So will be Invokana, and all other this family medicine. It is just matter of the number of our Deaths.
There are some comments to the article Anne Peters published.

A significant advance, Dr. Anne Peters. Thank you for your remarkable contribution. I sincerely hope that the post-marketing results with empagliflozin can crown your outstanding efforts.

empagliflozin was approved by FDA in 2014. It is medicine for Diabetic type 2, life long medicine. It is already carry on black box, which FDA palce in and takes off. So, less then 23 years, and medicine shot up its ugly face. Good crown for Anne Peters. She really very well fit for it.
Still, there are surprising comments. Not every one so excited. And there are many comments in right opposite direction:

 Neither exciting nor incredible, osmotic diuretics decrease blood pressure et improve slightly heart events. Small absolute gains are disguised in major relative-risk improvements : we must not forget denominators.

I love this comment more then anyone else.

Some feel that this drug "worked" by being a diuretic (recent pub in Diabetes Care) ... I tend to agree with this .... if this is the case, why not just use metformin and low dose thiazide.

Really, why do not give   just higher dose of diuretic, ether one, and then there is no diabetics so there is no rick for CVD. Simple and effective. To add more effect, add-on Metformin.The result is Guarantee. Also it is very cost effective too. $4 for Metformin. $4 for diuretic. Just less then $10 month, and the problem solved effectively and low costly. 

Your percentages, are they relative risk reduction, or absolute risk reduction? A 33% relative risk reduction is equal to approximately a 1.7% absolute reduction, or number needed to treat of 97 for one event change. So, without this information, your article is somewhat useless.

I really do not understand too much about %%% and ricks. What I do understand as Diabetic type 2 that

Even though investigators were encouraged to adjust glucose-lowering therapy according to local guidelines, many patients did not reach their glycemic targets, with an adjusted mean glycated hemoglobin level at week 206 of 7.81% in the pooled empagliflozin group and 8.16% in the placebo group.

Really I do not see big difference between medicine and placebo groups. At least with placebo there is no side effects such as extra trips to restrooms and medicine to treat urine tract infections. So, what is this medicine for in first place? Is this to treat heart which does not work well? Then why it is glucose lowering medicine must do the job? Simple, take medicine which work such as Nitrostat or Isosorbote to improve heart work, and do not mess one medical condition with another.  But if this medicine does not work to control blood sugar level in first place, then why I am, diabetic type 2, need it?

via Ravenvoron